Company intelligence / Profile preview

Intra-Cellular Therapies

New York, New York, United States of Americaintracellulartherapies.com ↗

Ownership: Public · ITCI
Employees: ~860
Development stage: Commercial

Overview

CAPLYTA (lumateperone) is FDA-approved for schizophrenia and depressive episodes associated with bipolar I or II disorder. The company has submitted an sNDA for CAPLYTA as an adjunctive treatment for major depressive disorder, which has been accepted for review by the FDA. Multiple Phase 2 and Phase 3 trials are ongoing for various indications.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

9 assets

lumateperone

Approved

8 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Intra-Cellular Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intra-Cellular Therapies.

Explore the full profile